Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B M Reipert

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology, Immunotherapy : CII|May 3, 2005
Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?B M Reipert, S Tanneberger, A Pannetta, et al.
Thrombosis and Haemostasis|January 5, 2002
Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune toleranceB M Reipert, M Sasgary, R U Ahmad, et al.
Vox Sanguinis|September 9, 2006
Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solutionB M Reipert, J Ilas, C Carnewal, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2018
In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implicationsK Canis, J Anzengruber, E Garenaux, et al.
Vox Sanguinis|February 13, 2008
Variation of anti-Fas antibodies in different lots of intravenous immunoglobulinB M Reipert, M T Stellamor, M Poell, et al.
Journal of Thrombosis and Haemostasis : JTH|July 28, 2009
Opportunities and limitations of mouse models humanized for HLA class II antigensB M Reipert, K N Steinitz, P M van Helden, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2010
Modulation of factor VIII-specific memory B cellsB M Reipert, P Allacher, C Hausl, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2010
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus reportJ Astermark, C Altisent, A Batorova, et al.
Blood Advances|November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor developmentB M Reipert, B Gangadharan, C J Hofbauer, et al.
Biologicals : Journal of the International Association of Biological Standardization|March 1, 2011
Taking immunogenicity assessment of therapeutic proteins to the next levelI C Büttel, P Chamberlain, Y Chowers, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology, Immunotherapy : CII|May 3, 2005
Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?B M Reipert, S Tanneberger, A Pannetta, et al.
Thrombosis and Haemostasis|January 5, 2002
Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune toleranceB M Reipert, M Sasgary, R U Ahmad, et al.
Vox Sanguinis|September 9, 2006
Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solutionB M Reipert, J Ilas, C Carnewal, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2018
In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implicationsK Canis, J Anzengruber, E Garenaux, et al.
Vox Sanguinis|February 13, 2008
Variation of anti-Fas antibodies in different lots of intravenous immunoglobulinB M Reipert, M T Stellamor, M Poell, et al.
Journal of Thrombosis and Haemostasis : JTH|July 28, 2009
Opportunities and limitations of mouse models humanized for HLA class II antigensB M Reipert, K N Steinitz, P M van Helden, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2010
Modulation of factor VIII-specific memory B cellsB M Reipert, P Allacher, C Hausl, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2010
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus reportJ Astermark, C Altisent, A Batorova, et al.
Blood Advances|November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor developmentB M Reipert, B Gangadharan, C J Hofbauer, et al.
Biologicals : Journal of the International Association of Biological Standardization|March 1, 2011
Taking immunogenicity assessment of therapeutic proteins to the next levelI C Büttel, P Chamberlain, Y Chowers, et al.
Pageof 2